Companies Dominating the Methicillin-resistant Staphylococcus Aureus Drugs Landscape
- BD (Becton, Dickinson, and Company)
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Melinta Therapeutics LLC
- Dr. Reddy’s Laboratories Ltd.
- Cardinal Health
- Pfizer Inc.
- Merck & Co., Inc.
- Baxter
- Crown Laboratories, Inc.
- Atlantic Biologicals
- Apollo Health & Beauty Care
Browse Key Market Insights with Data Illustration:
In the News
- BD (Becton, Dickinson, and Company) which is a leading international medical technology company, announced receiving a U.S. Food and Drug Administration (FDA) 510(k) clearance for its new BD Kiestra Methicillin-resistant Staphylococcus aureus (MRSA) imaging application. This imaging application leverages artificial intelligence (AI) to interpret bacterial growth and releases negative specimens with minimal human intervention.
- Melinta Therapeutics (Melinta) is a commercial-stage company that develops novel treatments for acute and life-threatening illnesses. The company recently announced the commercial launch of KIMYRSA (oritavancin), a lipoglycopeptide antibiotic that treats acute bacterial skin and skin structure infections (ABSSSI) completely with a single 1,200 mg infusion that takes one hour. On March 12, 2021, the U.S. Food and Drug Administration approved KIMYRSA for the treatment of adult patients with ABSSSI brought on by susceptible isolates of specific Gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA).
